editorin
chen
et
al
recent
studi
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sar
cov
igg
shown
persist
day
result
suggest
product
antibodi
depend
cell
might
play
role
protect
immun
sar
cov
hand
igm
found
decreas
becom
undetect
week
recoveri
phase
whether
survivor
sar
persist
antibodi
lifelong
immun
sar
cov
unknown
conduct
prospect
studi
investig
natur
cours
sar
cov
immunoglobulin
titer
survivor
sar
asymptomat
infect
healthcar
worker
describ
previou
report
serolog
test
perform
govern
viru
unit
hong
kong
china
follow
standard
protocol
serum
sampl
dilut
ml
dilut
sampl
incub
use
microscop
slide
coat
sar
covinfect
fetal
rhesu
kidney
cell
moist
chamber
min
slide
wash
chang
tween
sigma
fifteen
microlit
polyval
antihuman
immunoglobulin
label
fluorochrom
ad
slide
incub
min
follow
anoth
wash
chang
tween
slide
examin
use
fluoresc
microscop
lowpow
field
posit
signal
show
cytoplasm
fluoresc
confirm
examin
highpow
field
test
indetermin
result
repeat
uninfect
cell
exclud
nonspecif
reaction
result
quantifi
use
serial
titrat
serum
sampl
patient
report
titer
survivor
sar
studi
serum
sampl
collect
day
admiss
hospit
day
month
month
month
month
month
onset
sar
symptom
mean
age
survivor
sar
year
sd
year
male
femal
ratio
admiss
hospit
baselin
sar
cov
immunoglobulin
titer
fifteen
day
onset
symptom
mean
sar
cov
immunoglobulin
titer
figur
month
onset
symptom
mean
sar
cov
immunoglobulin
titer
increas
respect
afterward
gradual
decreas
mean
sar
cov
immunoglobulin
titer
observ
month
onset
symptom
ie
decreas
mean
titer
month
onset
symptom
compar
mean
titer
month
onset
symptom
asymptomat
infect
healthcar
worker
serum
sampl
collect
month
first
day
deploy
sar
ward
first
sar
cov
immunoglobulin
titer
figur
decreas
month
deploy
ie
decreas
titer
month
deploy
sar
cov
immunoglobulin
titer
previou
studi
report
time
neutral
antibodi
cov
decay
undetect
level
sar
human
antibodi
spike
protein
sar
cov
shown
neutral
effect
find
shown
survivor
sar
experi
minimum
decreas
sar
cov
immunoglobulin
titer
month
asymptomat
infect
healthcar
worker
studi
experienc
even
rapid
decreas
sar
cov
immunoglobulin
titer
remain
seen
whether
sar
cov
immunoglobulin
final
disappear
infect
person
progress
decreas
sar
cov
immunoglobulin
titer
impli
time
infect
person
may
experi
decreas
protect
immun
sar
cov
convalesc
serum
use
treat
patient
sar
hong
kong
part
china
expect
survivor
sar
high
level
sar
cov
immunoglobulin
basi
find
studi
convalesc
serum
ideal
collect
donor
month
onset
symptom
time
yield
sar
cov
immunoglobulin
would
highest
editorw
appreci
letter
tso
et
al
expand
studi
serolog
profil
sever
acut
respiratori
syndrom
sar
basi
find
studi
certain
igg
antibodi
persist
least
day
onset
symptom
consist
tso
et
al
result
despit
differ
assay
use
indic
sarsassoci
coronaviru
sar
cov
immunoglobulin
titer
continu
increas
day
month
onset
symptom
interestingli
rate
seroconvers
differ
studi
rate
seroconvers
report
studi
rate
seroconvers
report
tso
et
al
studi
may
consequ
differ
popul
patient
differ
assay
use
studi
tso
et
al
select
survivor
group
patient
sar
among
increas
sar
cov
immunoglobulin
singl
titer
first
month
followup
rate
seroconvers
patient
close
observ
day
day
accord
sever
report
immunofluoresc
assay
use
tso
et
al
sensit
elisa
use
studi
nevertheless
elisa
provid
similar
result
remain
conveni
reliabl
test
clinic
practic
epidemiolog
studi
